CONMED Q1 adjusted EPS $0.95, revenue $321.3M, raises FY2025 guidance

CONMED Corp

2025-Q1 EPS reported $0.19 revenue$321,256,000

Total sales $321.3M, up 2.9% reported (3.8% constant currency); domestic +4.2%, international +1.2%.
GAAP diluted EPS $0.19 vs $0.63 YoY, hit by $12.2M executive transition costs and $4.0M contingent consideration.
Adjusted diluted EPS $0.95, up 20% from $0.79; adjusted EBITDA $61.3M (19.1% margin) vs $56.3M.
FY2025 revenue guidance raised to $1.350-1.378B (prior $1.344-1.372B); adjusted EPS raised to $4.45-4.60 (prior $4.25-4.40).
Company estimates ~$0.14 negative tariff impact on EPS in H2 2025, not included in updated guidance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.